T1	Participants 666 844	patients attaining a negative early PET scan after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared with standard combined-modality treatment
T2	Participants 867 946	Patients age 15 to 70 years with untreated clinical stage I/II HL were eligible
T3	Participants 1301 1315	1,137 patients
